Difference between pages "IRAG1-AS1" and "LINC02885"

From LncRNAWiki
(Difference between pages)
Jump to: navigation, search
(Created page with "MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) can affect nasopharyngeal cancer (NPC) paclitaxel chemosensitivity <ref name="ref1" /> ==Annotated Inf...")
 
(Created page with "==Annotated Information== ===Name=== Approved symbol: LINC02885 Approved name: long intergenic non-protein coding RNA 2885 HGNC ID: HGNC:41188 Previous symbols...")
 
Line 1: Line 1:
MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) can affect nasopharyngeal cancer (NPC) paclitaxel chemosensitivity <ref name="ref1" />
+
==Annotated Information==
==Annotated Information==
+
===Name===
===Name===
+
Approved symbol: LINC02885
Approved symbol:IRAG1-AS1
 
 
 
Approved name:IRAG1 antisense RNA 1
 
 
 
HGNC ID:HGNC:43434
 
 
 
Previous name:MRVI1 antisense RNA 1 (non-protein coding)|MRVI1 antisense RNA 1
 
 
 
RefSeq ID:NR_034093
 
 
 
prev_symbol:MRVI1-AS1
+
Approved name: long intergenic non-protein coding RNA 2885
 
+
===Characteristics===
+
HGNC ID: HGNC:41188
Please input information here.
+
===Function===
+
Previous symbols: ISX-AS1
The2 MRVI1-AS1/ATF3 signaling pathway can increase NPC paclitaxel chemosensitivity by modulating the Hippo-TAZ signaling pathway.<ref name="ref1" />.
+
 
+
Previous names: ISX antisense RNA 1
===Regulation===
+
MRVI1-AS1 upregulated ATF3 (activating transcription factor 3) by simultaneously inhibiting miR-513a-5p (microRNA-513a-5p) and miR-27b-3p expression levels to increase NPC paclitaxel chemosensitivity.<ref name="ref1" />
+
RefSeq ID: NR_138042
 
 
MRVI1-AS1 and ATF3 could form a positive feedback loop, which promoted the expression of RASSF1 (Ras association domain family member 1), a Hippo-TAZ (tafazzin) signaling pathway regulatory factor, thereby inhibiting TAZ expression.<ref name="ref1" />
 
 
 
===Expression===
 
[[File: ''HOXC13-AS'' expression levels in tumors and cells.jpg|right|thumb|400px|'''''HOXC13-AS'' expression levels in tumors and cells' <ref name="ref1" />.]]
 
MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity. <ref name="ref1" />.
 
 
 
===Diseases===
 
* nasopharyngeal cancer (NPC) .<ref name="ref1" />
 
 
 
==Labs working on this lncRNA==
 
*Department of Oncology, Third Xiangya Hospital of Central South University, 410013, Changsha, People's Republic of China.<ref name="ref1" />
 
 
 
*Department of Respiration, The Second People's Hospital of Hunan Province of Hunan University of Chinese Medicine, Changsha, 410000, People's Republic of China.<ref name="ref1" />
 
 
 
*Institute of Reproductive and Stem Cell Engineering, Central South University, 410083, Changsha, Hunan, People's Republic of China.<ref name="ref1" />
 
 
 
*State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 510060, Guangzhou, People's Republic of China.<ref name="ref1" />
 
 
 
*Department of Plastic Surgery, Third Xiangya Hospital, Central South University, 410013, Changsha, Hunan, People's Republic of China.<ref name="ref1" />
 
 
 
*Department of Gastroenterology, Third Xiangya Hospital of Central South University, 410013, Changsha, People's Republic of China.<ref name="ref1" />
 
 
 
*Cancer Research Institute and Key Laboratory of Carcinogenesis of Ministry of Health, Central South University, 410078, Changsha, People's Republic of China.<ref name="ref1" />
 
 
 
*School of Public Health, Central South University, 410078, Changsha, Hunan, People's Republic of China.<ref name="ref1" />
 
 
 
*Center for Medical Experiments, Third Xiangya Hospital, Central South University, 410013, Changsha, People's Republic of China.<ref name="ref1" />
 
 
 
*Yan'an Affiliated Hospital of Kunming Medical University, 650051, Kunming, People's Republic of China.<ref name="ref1" />
 
 
 
*Department of Otolaryngology-Head Neck Surgery, Third Xiangya Hospital, Central South University, 410013, Changsha, Hunan, People's Republic of China.<ref name="ref1" />
 
 
 
*Department of Oncology, Third Xiangya Hospital of Central South University, 410013, Changsha, People's Republic of China. csucaoke@163.com.<ref name="ref1" />
 
 
 
==References==
 
<references>
 
<ref name="ref1">Zhu Y, He D, Bo H, Liu Z, Xiao M, Xiang L, Zhou J, Liu Y, Liu X, Gong L, Ma Y, Zhou Y, Zhou M, Xiong W, Yang F, Xing X, Li R, Li W, Cao K. The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway. Oncogene. 2019 Aug;38(32):6065-6081. doi: 10.1038/s41388-019-0858-7. Epub 2019 Jul 4. PMID: 31273338.</ref>
 
</references>
 

Latest revision as of 03:20, 29 January 2021

Annotated Information

Name

Approved symbol: LINC02885

Approved name: long intergenic non-protein coding RNA 2885

HGNC ID: HGNC:41188

Previous symbols: ISX-AS1

Previous names: ISX antisense RNA 1

RefSeq ID: NR_138042